RE: phenergan

[Heather Nichols]

Title: Message

Ask the pharmacist if he/she can explain to you why phenergan burns like liquid fire when it is injected into the "good vein", but not when it is given centrally.   Heather Nichols RN BSN CRNI Infusion Services University of Louisville Trauma Institute 530 S. Jackson St. Lou. Ky. 40202 (502)562-3530 >>> "Feckers, Charlotte" <[EMAIL PROTECTED]> 03/01/06 3:16 PM >>> To the group:  I read this e-mail this am and sure enough we had a Doc order phenergan 12.5 Iv I spoke up and said it had just been on the link how bad it was.  He and the pharmacist both told me it was fine to give as long as you make sure you have a good vein.... Not a central line but a good vein.  The pharmacist told me if it was as bad as I was saying we would have had it pulled from the shelves.  Anyone out there this afternoon with some good come backs I don't have a lot of time this afternoon to research articles. Thanks in advance Charlotte RNCRNI  -----Original Message----- From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED] On Behalf Of Lynn Hadaway Sent: Wednesday, March 01, 2006 10:54 AM To: Kilbourne, Susan; [EMAIL PROTECTED]; [EMAIL PROTECTED] Subject: Re: phenergan While there are numerous lawsuits involving promethazine injuries, there is not much that has ever been published. The following are the only ones that I know of: Extravasation of I.V. promethazine      M. Malesker, P. Malone, C. Cingle, R. Cochran   American journal of health-System pharmacy      unusual drug experiences, FDA, promethazine injection, intra-arterial injection, extravasation, dominal hysterectomy    05-14-01        Vol. 56, September 1, 1999      1742-1743       2049    Case Report Accidental intra-arterial injection of promethazine HCI during general anesthesia: report of a case     H. Mostafavi, M. Samimi Anesthesiology  intra-arterial injection, promethazine hydrochloride (Phenergan), anesthesia    10-30-02        Vol. 35, No. 6, December 1971   645-646 2836    Case Report Promethazine adverse events after implementation of a medication shortage interchange.  H. Sheth, M. Verrico, S. Skedar, A. Towers      Ann Pharmacother        promethazine, adverse events,   11-11-5 Volume 39, Number 2, February 2005      255-261 5265    Abstract Adverse reactions related to phenergan  C. Blankenship  Gastroenterology Nursing        Phenergan, arterial misplacement, PICC, pediatrics, seizure activity    11-04-04        Volume 24, Number 3     149-150 3985    Review At 5:23 PM -0800 2/28/06, Kilbourne, Susan wrote: We are finally having a team meeting at our hospital to discuss the use of IV phenergan through peripheral lines after having two problems in the past year. The problem is convincing the MDs. Can anyone point me to some specific literature to support of dangers of infiltrated phenergan? Thanks in advance, Sue Kilbourne CRNI, OCN NOTE: The information contained in this message may be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the message and deleting it from your computer. E-mail has the potential to have been altered or corrupted due to transmission or conversion. It may not be appropriate to rely upon this E-mail in the same manner as hardcopy materials bearing the author's original signature or seal. Thank you. Asante® Health System -- Lynn Hadaway, M.Ed., RNC, CRNI Lynn Hadaway Associates, Inc. 126 Main Street, PO Box 10 Milner, GA 30257 http://www.hadawayassociates.com office 770-358-7861 Privileged/Confidential information may be contained in this message. The information contained in this message is intended only for the use of the recipient(s) named above and their co-workers who are working on the same matter. The recipient of this information is prohibited from disclosing the information to any other party unless this disclosure has been authorized in advance. If you are not intended recipient of this message or any agent responsible for delivery of the message to the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this message is strictly prohibited. You should immediately destroy this message and kindly notify the sender by reply E-Mail. Please advise immediately if you or your employer does not consent to Internet E-Mail for messages of this kind. Opinions, conclusions and other information in this message that do not relate to the official business of the firm shall be understood as neither given nor endorsed by it. ----------------------------------------------------- Confidentiality Disclaimer This message, including any attachments, is confidential, intended only for the named recipient(s) and may contain information that is privileged or exempt from disclosure under applicable law, including PHI (Protected Health Information) covered under the Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If you are not the intended recipient(s), you are notified that the dissemination, distribution, or copying of this message is strictly prohibited.  If you receive this message in error, or are not the named recipient(s), please notify the sender or contact the University of Louisville Health Care I.S. helpdesk at 502.562.3637 to report an inadvertently received message. -----------------------------------------------------

BEGIN:VCARD
VERSION:2.1
X-GWTYPE:USER
FN:Nichols, Heather
TEL;WORK:562-3530
ORG:;IV specialist
EMAIL;WORK;PREF;NGW:[EMAIL PROTECTED]
N:Nichols;Heather
TITLE:RN
END:VCARD